In a report released today, Steven Lichtman from Oppenheimer maintained a Buy rating on Organogenesis Holdings (ORGO), with a price target of $9.00. The company’s shares closed last Monday at $3.09, close to its 52-week low of $3.00.
According to TipRanks.com, Lichtman has currently no stars on a ranking scale of 0-5 stars, with an average return of -5.3% and a 48.0% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Merit Medical Systems, and Integra Lifesciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Organogenesis Holdings with a $8.67 average price target, implying a 147.7% upside from current levels. In a report issued on March 6, Credit Suisse also reiterated a Buy rating on the stock with a $8.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $14.30 and a one-year low of $3.00. Currently, Organogenesis Holdings has an average volume of 74.83K.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ORGO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.